Ertugliflozin; Sitagliptin Phosphate Patent Expiration
Ertugliflozin; Sitagliptin Phosphate is used for improving glycemic control in adults with type 2 diabetes. It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Ertugliflozin; Sitagliptin Phosphate Patents
Given below is the list of patents protecting Ertugliflozin; Sitagliptin Phosphate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Steglujan | US9308204 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | Oct 21, 2030 | Msd Sub Merck |
| Steglujan | US9439901 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | Oct 21, 2030 | Msd Sub Merck |
| Steglujan | US8080580 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | Jul 13, 2030 | Msd Sub Merck |
| Steglujan |
US7326708 (Pediatric) | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | May 24, 2027 | Msd Sub Merck |
| Steglujan | US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | Nov 24, 2026 | Msd Sub Merck |
| Steglujan |
US6699871 (Pediatric) | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan 26, 2023
(Expired) | Msd Sub Merck |
| Steglujan | US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul 26, 2022
(Expired) | Msd Sub Merck |
| Steglujan | US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Msd Sub Merck |
| Steglujan | US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Msd Sub Merck |
| Steglujan | US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Msd Sub Merck |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ertugliflozin; Sitagliptin Phosphate's patents.
Latest Legal Activities on Ertugliflozin; Sitagliptin Phosphate's Patents
Given below is the list recent legal activities going on the following patents of Ertugliflozin; Sitagliptin Phosphate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 27 Jun, 2024 | US8080580 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 May, 2023 | US8080580 |
| Second letter to regulating agency to determine regulatory review period | 22 Apr, 2021 | US8080580 |
| Second letter to regulating agency to determine regulatory review period | 15 Apr, 2021 | US8080580 |
| Letter from FDA or Dept of Agriculture re PTE application | 12 Jun, 2019 | US8080580 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 May, 2019 | US8080580 |
| Initial letter Re: PTE Application to regulating agency | 15 Oct, 2018 | US8080580 |
| Patent Term Extension Application under 35 USC 156 Filed | 15 Feb, 2018 | US8080580 |
| Recordation of Patent Grant Mailed Critical | 20 Dec, 2011 | US8080580 |
| Patent Issue Date Used in PTA Calculation Critical | 20 Dec, 2011 | US8080580 |
Ertugliflozin; Sitagliptin Phosphate's Family Patents
